| Sofosbuvir for previously untreated chronic hepatitis C infection E Lawitz, A Mangia, D Wyles, M Rodriguez-Torres, T Hassanein, ... New England Journal of Medicine 368 (20), 1878-1887, 2013 | 2454 | 2013 |
| Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Afdhal, S Zeuzem, P Kwo, M Chojkier, N Gitlin, M Puoti, ... New England Journal of Medicine 370 (20), 1889-1898, 2014 | 2188 | 2014 |
| Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection JJ Feld, IM Jacobson, C Hézode, T Asselah, PJ Ruane, N Gruener, ... New England Journal of Medicine 373 (27), 2599-2607, 2015 | 1390 | 2015 |
| Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ... New England Journal of Medicine 373 (27), 2608-2617, 2015 | 1084 | 2015 |
| Sofosbuvir and ribavirin in HCV genotypes 2 and 3 S Zeuzem, GM Dusheiko, R Salupere, A Mangia, R Flisiak, RH Hyland, ... New England Journal of Medicine 370 (21), 1993-2001, 2014 | 1038 | 2014 |
| Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 A Mangia, R Santoro, N Minerva, GL Ricci, V Carretta, M Persico, F Vinelli, ... New England Journal of Medicine 352 (25), 2609-2617, 2005 | 848 | 2005 |
| Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: a retrospective study S Bruno, T Stroffolini, M Colombo, S Bollani, L Benvegnu, G Mazzella, ... Hepatology 45 (3), 579-587, 2007 | 768 | 2007 |
| Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data G Leandro, A Mangia, J Hui, P Fabris, L Rubbia–Brandt, G Colloredo, ... Gastroenterology 130 (6), 1636-1642, 2006 | 689 | 2006 |
| A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis SA Harrison, P Bedossa, CD Guy, JM Schattenberg, R Loomba, R Taub, ... New England Journal of Medicine 390 (6), 497-509, 2024 | 611 | 2024 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 406 | 2020 |
| An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response A Mangia, AJ Thompson, R Santoro, V Piazzolla, HL Tillmann, K Patel, ... Gastroenterology 139 (3), 821-827. e1, 2010 | 399 | 2010 |
| Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial A Mangia, N Minerva, D Bacca, R Cozzolongo, GL Ricci, V Carretta, ... Hepatology 47 (1), 43-50, 2008 | 340 | 2008 |
| Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis A Andriulli, G Leandro, G Niro, A Mangia, V Festa, G Gambassi, ... Gastrointestinal endoscopy 51 (1), 1-7, 2000 | 320 | 2000 |
| Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis KR Reddy, M Bourlière, M Sulkowski, M Omata, S Zeuzem, JJ Feld, ... Hepatology 62 (1), 79-86, 2015 | 313 | 2015 |
| Prophylaxis and treatment of hepatitis B in immunocompromised patients A Marzano, E Angelucci, P Andreone, M Brunetto, R Bruno, P Burra, ... Digestive and Liver Disease 39 (5), 397-408, 2007 | 288 | 2007 |
| The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype‐specific mechanisms V Pazienza, S Clément, P Pugnale, S Conzelman, M Foti, A Mangia, ... Hepatology 45 (5), 1164-1171, 2007 | 287 | 2007 |
| NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome S Zeuzem, M Mizokami, S Pianko, A Mangia, KH Han, R Martin, ... Journal of hepatology 66 (5), 910-918, 2017 | 268 | 2017 |
| Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts P Duggal, CL Thio, GL Wojcik, JJ Goedert, A Mangia, R Latanich, AY Kim, ... Annals of internal medicine 158 (4), 235-245, 2013 | 258 | 2013 |
| Noninvasive Diagnosis of NAFLD and NASH VA Piazzolla, A Mangia Cells 9 (4), 1005, 2020 | 245 | 2020 |
| SAFE biopsy: a validated method for large‐scale staging of liver fibrosis in chronic hepatitis C G Sebastiani, P Halfon, L Castera, S Pol, DL Thomas, A Mangia, ... Hepatology 49 (6), 1821-1827, 2009 | 241 | 2009 |
